金振口服液联合抗生素对小儿支原体肺炎的临床治疗效果

目的　研究金振口服液结合抗生素治疗方案对支原体肺炎（MPP）患儿的临床治疗效果，以及对第1秒用力呼气容积（FEV1）、呼气峰流速（PEF）、第1秒用力呼气容积与用力肺活量比值（FEV1/FVC）指标的影响。方法　选取2021年1月至2022年2月郑州大学附属郑州中心医院儿科MPP患儿130例，用随机数字表法对其进行分组，其中将65例单数对应患儿列为对照组，男30例、女35例，年龄（5.42±0.33）岁，采用抗生素作常规抗菌治疗；将65例双数对应患儿列为观察组，男31例、女34例，年龄（5.37±0.41）岁，采用金振口服液+抗生素治疗。对比两组肺功能、炎性反应、免疫功能、症状缓解时间，评估治疗有效性及治疗安全性。计量资料采用t检验，计数资料采用χ²检验。结果　治疗后，观察组FEV1、PEF、FEV1/FVC及CD3+、CD4+、CD4+/CD8+指标分别为（88.94±0.14）%、（549.72±15.16）L/min、（79.49±2.24）、（67.92±2.82）%、（58.24±2.26）%、（1.82±0.49），均高于对照组［（86.14±0.23）%、（531.32±15.44）L/min、（76.14±2.31）、（65.14±2.12）%、（55.32±2.17）%、（1.55±0.12）］，差异均有统计学意义（均P<0.05）。治疗后，观察组C-反应蛋白（CRP）、降钙素原（PCT）、血清淀粉样蛋白A（SAA）指标分别为（0.52±0.14）mg/L、（0.25±0.07）µg/L、（10.12±1.15）mg/L，均低于对照组［（0.79±0.36）mg/L、（0.46±0.19）µg/L、（12.71±1.62）mg/L］，差异均有统计学意义（均P<0.05）。观察组治疗后退热时间、咳嗽缓解时间、气喘恢复时间、肺部啰音消失时间分别为（3.23±0.15）d、（6.62±0.42）d、（3.36±0.31）d、（4.15±0.32）d，均低于对照组［（4.46±0.33）d、（8.25±0.39）d、（5.12±0.44）d、（5.82±0.36）d］，差异均有统计学意义（均P<0.05）。观察组治疗后不良反应发生率为9.23%（6/65），与对照组7.69%（5/65）比较，差异无统计学意义（χ²=0.153，P=0.696）。结论　在MPP患儿的抗菌治疗中联合金振口服液可在增强疗效同时保证用药安全。

Clinical effect of Jinzhen oral liquid combined with antibiotics onchildren with mycoplasma pneumonia

Objective　To study the clinical therapeutic effect of Jinzhen oral liquid combinedwith antibiotics on children with mycoplasma pneumonia (MPP), and itsinfluences on forced expiratory volume in 1 second (FEV1), peak expiratory flow(PEF), ratio of forced expiratory volume in 1 second to forced vital capacity(FEV1/FVC). Methods　The cases wereselected from January 2021 to February 2022, all from Department of Pediatrics,Zhengzhou Central Hospital Affiliated to Zhengzhou University, and a total of130 children with MPP were included. They were divided into two groups by therandom number table method, among them 65 children with odd numbers wereclassified as the control group, and 65 children with even numbers wereclassified as the observation group. In the control group, there were 30 malesand 35 females, aged (5.42±0.33) years; in the observation group, there were 31males and 34 females, aged (5.37±0.41) years. The control group receivedantibiotics as routine antibacterial treatment, and the observation group wastreated with Jinzhen oral liquid + antibiotics. The pulmonary function,inflammatory response, immune function, symptom relief time were comparedbetween the two groups, and the efficacy and safety of treatment wereevaluated. t test was used for the measurementdata, and chi-square test was used for the count data. Results　After treatment, the indexes of FEV1, PEF, FEV1/FVC, CD3+, CD4+, andCD4+/CD8+ in the observation group were (88.94±0.14) %, (549.72±15.16) L/min,(79.49±2.24), (67.92±2.82) %, (58.24±2.26) %, and (1.82±0.49), which werehigher than those in the control group [(86.14±0.23) %, (531.32±15.44) L/min,(76.14±2.31), (65.14±2.12) %, (55.32±2.17) %, and (1.55±0.12)], withstatistically significant differences (all P<0.05).After treatment, the indexes of C-reactive protein (CRP), procalcitonin (PCT),and serum amyloid A (SAA) in the observation group were (0.52±0.14) mg/L,(0.25±0.07) µg/L, and (10.12±1.15) mg/L, which were lower than those in thecontrol group [(0.79±0.36) mg/L, (0.46±0.19) µg/L, and (12.71±1.62) mg/L], withstatistically significant differences (all P<0.05).The antipyretic time, cough relief time, asthma recovery time, lung ralesdisappearance time of the observation group after treatment were (3.23±0.15) d,(6.62±0.42) d, (3.36±0.31) d, and (4.15±0.32) d, which were lower than those inthe control group [(4.46±0.33) d, (8.25±0.39) d, (5.12±0.44) d, and (5.82±0.36)d], with statistically significant differences (all P<0.05). The incidence of adverse reactions after treatment inthe observation group was 9.23% (6/65), without statistically significantdifference compared with 7.69% (5/65) in the control group (χ²=0.153, P=0.696). Conclusion　In the antibacterial treatment of children with MPP, Jinzhen oral liquidcan enhance the curative effect and ensure the safety of medication.